Will Roettger

oncology market research leukemia biotechnology lymphoma nsclc pharmaceutical marketing cll oncology drug development hematology dlbcl hematology-oncology genentech lambrolizumab nivolumab roche pidilizumab bristol myers squibb mpdl3280a melanoma merck competitive intelligence crc colorectal cancer drug development cancer treatment multiple myeloma aml all targeted agents oncology reports idealilisib ibrutinib duvelisib chronic lymphocytic leukemia drug development strategy clinical drug development commercial drug development oncology drug treatments market assessments drug profiling drug launch prediction car-t cell market assessment acute lymphocytic leukemia reports nhl curetech bms936559 immune checkpoints programmed death-1 renal cell carcinoma ctla-4 pd-1. pd-l1 rare disease cold agglutinin disease cad rituximab rituxan plasmapheresis anemia aiha autoimmune hemolytic anemia immunotherapy bms936558 mk-3475 pd-1 pd-l1 ct-011 eli lilly duration-4 novo nordisk byetta metformin pioglit bydureon amylin actos exenatide. januvia alkermes afatanib bif1120 tomtovok nintedanib clinical trial stivarga sorafenib regorafenib nexavar bay 73-4506 oncology products bayer oncology non small cell lung cancer market research plan product launch avastin erbitux schizophrenia anti-psychotic pharmaceutical drugs boehringer ingelheim tovok vargatef neurogenic orthostatic hypotension noh chelsea therapeutics northera drug launch plan pharmaceutical drug